KRAS and non-small cell lung carcinoma: Subgroup analysis in the CheckMate057 study showed that the OS benefit of nivolumab monotherapy as second-line treatment was better than that of docetaxel in NSCLC patients with KRAS mutations (HR = 0.52; 95% CI: 0.29–0.95), whereas the OS benefit was limited in patients with KRAS-wild-type NSCLC (HR = 0.98; 95% CI: 0.29–0.95) [16].